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Abstract
Background: An understanding of growth dynamics of tumors is important in understanding progression of
cancer and designing appropriate treatment strategies. We perform a comparative study of the hyperbolastic
growth models with the Weibull and Gompertz models, which are prevalently used in the field of tumor growth.
Methods: The hyperbolastic growth models H1, H2, and H3 are applied to growth of solid Ehrlich carcinoma
under several different treatments. These are compared with results from Gompertz and Weibull models for the
combined treatment.
Results: The growth dynamics of the solid Ehrlich carcinoma with the combined treatment are studied using
models H1, H2, and H3, and the models are highly accurate in representing the growth. The growth dynamics are
also compared with the untreated tumor, the tumor treated with only iodoacetate, and the tumor treated with
only dimethylsulfoxide, and the combined treatment.
Conclusions: The hyperbolastic models prove to be effective in representing and analyzing the growth dynamics
of the solid Ehrlich carcinoma. These models are more precise than Gompertz and Weibull and show less error for
this data set. The precision of H3 allows for its use in a comparative analysis of tumor growth rates between the
various treatments.
Background
A precise mathematical formulation of biological growth
is an important problem that applies to many areas of
biology and can have a significant impact on understand-
ing of growth dynamics. The application of mathematical
models to understand the growth of cancer cells is a
prime example, and many researchers have explored this
important area. An integral part of this analysis is the
choice of an appropriate growth model, and the right
model can eventually aide the researcher in having a bet-
ter understanding of the progression and regression of
the tumor size and its associated velocity and accelera-
tion. Sigmoidal, or logistic type growth models have been
used because of the regression of the growth rate with
the progression of the tumor, and the Gompertz model
has been widely used in representing tumor growth. In
2005, Tabatabai et al. [1] introduced three flexible
growth dynamic models called hyperbolastic growth
models H1, H2, and H3. These models give a highly
accurate estimate of parameters with low estimates of
standard deviation. The hyperbolastic models have been
used to analyze various biomedical problems, for instance
polio data in [1], craniofacial size in [2], and dynamics of
broiler growth in [3], and have always performed with a
high degree of accuracy and precision. More recently
these models have been shown to be the most accurate
in describing dynamics of cellular proliferation for
embryonic [2] stem cells. In [1] these models were also
shown to be the most accurate in describing the growth
of multicellular tumor spheroids in a malignant brain
tumor. This paper applies the hyperbolastic models to
growth of solid Ehrlich carcinoma, both in the form of
growth inhibited only through the natural immune
response and in the form of growth retarded through
treatment with iodoacetate and dimethylsulfoxide. We
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combined treatment.
Analysis of the growth dynamics of tumors can lead to
an increased understanding in the causes for acceleration
and deceleration of the rate of tumor proliferation, and
furthermore an accurate quantitative knowledge of
tumor growth dynamics can be applied directly to design
of an optimal treatment strategy. The study of Cabrales
et al. [4] applied the Gompertz model to describe Ehrlich
tumor growth, and its effect under electrical stimulation,
in order to help physicians design appropriate treatment
plans. A sigmoidal model is needed in order to capture
the self-limiting growth of tumors in which the growth
rate decelerates with increasing age. Lala [5] stated the
importance of studying the causes behind the decelera-
tion of solid tumor growth rate, identifying possible
causes to include prolonged mitotic cycle, decrease in the
proliferative fraction of the tumor cells, or increases in
the rate of cell loss. Recently Araujo and McElwain [6]
have studied vascular collapse in relation to tumor
growth rate, which has a direct effect on delivery of nutri-
ents and delivery of anti-cancer drugs. Komarova et al.
[7] have applied optimal control theory to formulate a
theory in which the genetic instability and mutation
within cancer cells lead to the decreased proliferation
and self-limiting growth observed in solid tumors. Accu-
rate models to describe tumor growth can lead to
increased understanding of the growth dynamics and to
improvements in understanding of tumor growth and
improvements in treatment regimes.
T h ep u r p o s eo ft h i sa r t i c l ei st op r e s e n tt h eh y p e r b o -
lastic models, and particularly H3, as highly effective
and highly accurate tools in modelling the growth of
solid tumors. For purposes of comparison, these models
are compared with the Weibull model and particularly
with the Gompertz model, which is the most prevalently
used model in the field of tumor growth. Application of
these growth models yields an explicit function repre-
senting the size of the tumor, as well as an explicit func-
tion representing the rate of growth. These functions
allow for an analysis of the tumor growth dynamics, and
we observe in the study that they are equally effective in
an untreated tumor as in the cases of a single or com-
bined treatment. Thus the study of growth dynamics
can be applied to study the effectiveness of a given
treatment. The article demonstrates this type of analysis
in the representative case of treatment by IAA, DMSO,
or both, found in Fahim et al. [8], and the mathematical
analysis provides new insight to the combined treat-
ment. We briefly survey the means of action of these
two anti-cancer drugs.
Iodoacetate is one anti-cancer drug which may decele-
rate the rate of cancer cell proliferation, and it acts
through disruption of tumor cell metabolism. Miko et al.
[9] studied the impact of dactylarin as an anti-cancer
agent which disables cells through inhibition of the gly-
colysis and energy generating pathways of the cells. The
resulting impact on cancer cells through disruption of
key steps in energy metabolism was observed to be simi-
lar to the effects of iodoacetate. Scatena et al. [10] discuss
the importance of drugs which disturb cancer cell glyco-
lysis in cancer therapies. They describe five potential
actions of such drugs on cancer cells and propose further
study of the unique metabolism displayed by cancer cells.
Boros et al. [11] discuss the role of pentose phosphate
pathways (PPP) in tumor proliferation and propose to
investigate newer cancer treatments blocking specific
reactions within the PPP. Badwey and Karnovshy [12]
report that iodoacetate inhibits two important enzymes
in the oxidative stage with the PPP. As an anti-cancer
drug iodoacetate acts through disruption of metabolism
within the tumor cells to prevent proliferation.
The use of dimethylsulphoxide to slow the proliferation
of cancer is based on a different method of action, primar-
ily the stimulation of the quiescent phase within the can-
cer cells. Dimethylsulfoxide is commonly used as a solvent
because of its ease in passing cellular and vascular mem-
branes, and it is well known to induce differentiation.
Higgins and O’Donnell [13] noticed a dose-dependent
reduction in proliferation of murine hepatoma cells
exposed to dimethylsulfoxide. Higgins [14] determined
that the dimethylsulfoxide suppresses cellular proliferation
through a substantial reduction in the cellular RNA con-
tent and stimulation of the quiescence in the exposed cells.
Fahim et al. [8] propose to use both iodoacetate and
dimethylsulfoxide in a combined treatment in order to
combine the effects of each drug. The induction of cel-
lular quiescence by the DMSO and the disruption of
cellular metabolism by IAA affect two different aspects
of cellular growth, and they are expected to combine for
a greater effect.
Methods
Tabatabai et al. [1] introduced the hyperbolastic growth
models. The first of the three differential equations is
called the hyperbolastic growth rate of type I (H1)
which has the equation of the form
dP t
dt
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where P(t) is the population size at time t,t h ec o n -
stant M is the parameter representing carrying capacity,
and δ and θ jointly determine the growth rate. The
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from a symmetric sigmoidal distribution. Solving the
equation (1) for the population size P gives
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and arcsinh(t) is the inverse hyperbolic sine function
of t. We call the function P(t) of equation (2) the hyper-
bolastic growth model of type I or simply H1.
The second differential equation which was developed
earlier is called the hyperbolastic growth rate of type II
(H2) and has the form
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with the initial condition P(t0)=P0 and g >0 ,w h e r e
tanh[.] stands for hyperbolic tangent function. M is the
parameter representing the carrying capacity, and the
parameters δ and g jointly determine the growth rate.
The parameter g represents acceleration in the time
course. Solving the equation (3) for population size P
gives
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Finally, we consider the third growth curve through
the following nonlinear hyperbolastic differential equa-
tion of the form
dP t
dt
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with the initial condition P(t0)=P0. The parameter M
represents the carrying capacity, and the parameters δ,
g,a n dθ jointly determine the growth rate. The para-
meter g represents acceleration of the time scale, while
t h es i z eo fθ represents distance from a symmetric sig-
moidal curve. We refer to the model (5) as the hyperbo-
lastic ordinary differential equation of type III or H3.
The solution to the equation (5) is
Pt M E X P t t () [ ( ) ] =− − −  
 arcsinh (6)
where
 
 =− + () [ ( ) ] . MP E X Pt t 00 0 arcsinh
We call the function P(t) of equation (6) the hyperbo-
lastic growth model of type III or simply H3. If neces-
sary, one can introduce shift or delay parameters in any
or all hyperbolastic growth models.
The parameters are estimated using computational
software SPSS and Mathematica to produce a best fit to
the experimental data. It is also possible to use the SAS
package. For instance the method of non-linear least
squares regression for the H3 model (6) is used to
determine the model parameters. Using SPSS, the input
data can be analyzed using the Nonlinear Regression
module, found under Analyze and Regression. After
entering formula (6) into the box for Model Expression,
it is then necessary to enter initial value estimates for
the parameters. In SPSS, the arcsinh(x) function must
be entered using its definition in terms of logarithms:
arcsinh( ) ln( ) xx x =+ + 1
2 . An example of the source
code used to estimate the parameters in SAS can be
found in the additional file of [1].
Note that P′(t) and P′(t), the velocity and acceleration of
growth, can be explicitly determined, as functions of time,
once the parameters for P(t) have been determined. Math-
ematica is an effective tool for computation of P′(t)a n d
P′(t), as well as for their use in studying cancer growth
dynamics. Description of rate of growth as an explicit
function P′(t) is more accurate and realistic than use of
a static parameter, for instance. The explicit functions and
P′(t) allow for a deeper analysis of the growth dynamics.
The same methods of analysis and curve fitting will
also be applied to the data using the Gompertz model,
of the following form:
P t EXP bEXP ct () [ [ ] ] = 
where
 =∗ − P EXP bEXP ct 00 [ [ ]].
for initial conditions P(t0)=P0 The parameters b and
c satisfy b, c < 0. These methods will also be applied to
the Weibull model of the form
Pt M E X P t () ( ) =− − 

where M, b, and g are model parameters and

 =− () ( ) . MP E X Pt 00
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Fahim et al. [8] analyzed the survival times of mice by
investigating the effect of the anti- tumor treatments
iodoacetate, dimethylsulfoxide, and the combined treat-
ment effect of both iodoacetate and dimethylsulfoxide
on the retardation of solid Ehrlich carcinoma. As men-
tioned in the background, they demonstrated that the
disruption of cell metabolism by iodoacetate and the sti-
mulation of cellular senescence by dimethylsulfoxide
complement one another and produce a greater com-
bined effect. The researchers recommend the combined
treatment by iodoacetate (IAA) and dimethylsulphxide
(DMSO) as an appropriate action to be taken, and their
data supports the strengthened effect of combining
these two anti-cancer chemicals.
In this section, we first apply the hyperbolastic growth
models H1, H2, and H3 to their data in order to obtain
predictive growth functions for the growth dynamics of
the mean tumor weights after receiving the combined
treatment of iodoacetate and dimethylsulfoxide. For pur-
poses of comparison, the Gompertz and Weibull models
are also fit to the same data. Table 1 gives the para-
meter values, as estimated using SPSS, for all the mod-
els, hyperbolastic, Gompertz, and Weibull. In addition
Table 2 compares the observed value with the predicted
value for each of the models H1, H2, H3, Gompertz,
and Weibull.
All three of the hyperbolastic models are seen to be
highly accurate in representing the growth of the treated
tumors, while the model H3 shows a higher accuracy
than the others. These all compare favourably to Gom-
pertz, as can be seen in Table 2 above. See also Figure 1
below, which shows the actual data and a comparison of
the fit between H3 and Gompertz growth curves. Table
3 below gives a comparison of accuracies in the esti-
mates given by hyperbolastic models H1 to H3 and also
the Weibull and Gompertz models. Note that although
these results are for the data set for solid Ehrlich carci-
noma with a combined treatment of IAA and DMSO,
the results for each of the treated cases, IAA alone and
DMSO alone, and for the untreated case are similar.
The measures of accuracy in Table 3 are Akaike infor-
mation criterion (AIC), residual mean square (RMS), R
2,
and mean absolute relative error (MARE). The measure-
ment of AIC is used in model selection to compare dif-
ferent models with different number of parameters. The
model with the lowest AIC value is considered the best.
Clearly the best of the above models is H3, by all of
the measures of accuracy given in Table 3. This model
will be compared further with the Gompertz model,
which is the model most prevalently used in tumor
growth modelling. Observe in Tables 2 and 3 and Fig-
ures 1 and 2 that for the current data set the estimated
values given by Gompertz are really some distance from
the actual values. Figure 1 compares the actual values to
the H3 and Gompertz estimates. The H3 growth curve
is solid while the Gompertz curve is dashed. This inac-
curacy is further magnified in measurement of the
growth rate, whereas an accurate estimate of this rate is
critical in applications and in design of an optimal treat-
ment regimen. Figure 2 shows a comparison of the
growth rates with H3 a solid curve and Gompertz a
dashed curve.
T h eg r o w t hr a t ef o rt h et u m o rw e i g h to ft h eS o l i d
Ehrlich Carcinoma for a combined treatment group
using hyperbolastic H1 reaches its maximum of
0.172765 grams per day on the day 55.4873 but for the
hyperbolastic H2 and H3, the maximum rates are
0.175028 and 0.184104 grams per day and occur on the
days 55.2494 and 57.2509 respectively. All of these are
comparable in both the size of the maximum and the
time of occurrence. Although all of these give results
that are fairly similar and close to the exact values, the
estimate by Gompertz is considerably off the mark, esti-
mating a maximum rate of 0.146143 grams per day on
day 67.5891. The distance of Gompertz from the correct
prediction of the rate of growth can be clearly seen in
Figure 2 above.
Using the most accurate of the above models, H3, we
also make a comparative analysis of the growth of the
solid Ehrlich carcinoma cells under the various treat-
ments: combined treatment of iodoacetate and
dimethylsulfoxide, treatment by only iodoacetate, treat-
ment by only dimethylsulfoxide, and the control of no
Table 1 Parameter estimates for the Solid Ehrlich
Carcinoma treated with combined IAA and DMSO using
models H1, H2, H3, Gompertz, and Weibull
Model Parameter Estimate Std.
Dev.
95% Confidence
Interval
Lower
Bound
Upper
Bound
M 8.298 0.190 7.893 8.703
H1 δ 0.087 0.006 0.074 0.100
θ -0.206 0.141 -0.506 0.094
M 8.223 0.204 7.787 8.659
H2 δ 0.055 0.014 0.025 0.085
g 1.088 0.061 0.958 1.129
M 7.533 0.098 7.322 7.744
H3 δ 3.594E-9 0.000 -4.822E-9 1.201E-8
g 4.712 0.265 4.143 5.281
θ 0.004 0.001 0.003 0.005
Gompertz b -5.418 0.071 -5.570 -5.267
c -0.025 0.002 -0.028 -0.022
M 8.024 0.235 7.523 8.524
Weibull b -8.579E-7 0.000 -1.807E-6 9.076E-8
g 3.399 0.139 3.103 3.696
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these is shown in Figure 3. The solid curve represents
the untreated tumors, the dashed curve represents treat-
ment by IAA, the dotted curve represents treatment by
DMSO, and the dotted and dashed curve represents the
combined treatment. The observed values are plotted
together with these growth curves in Figure 3, and the
graph clearly indicates the H3 model estimates the data
accurately. In these other treatments the tumor growth
stopped sooner than in the combined treatment, at the
time of death of the experimental mice. In all cases, the
rate of growth initially increases with increasing tumor
size. The deceleration of this rate with increasing age
and size of the tumor is the object of study proposed by
Lala [5]. Our analysis gives a mathematical representa-
tion of the dynamics of this growth rate. Figure 4 shows
the rates of growth for each of these cases. The solid
curve represents the untreated tumors, the dashed curve
represents treatment by IAA, the dotted curve repre-
sents treatment by DMSO, and the dotted and dashed
curve represents the combined treatment. The untreated
tumors clearly reach a much higher rate of increase,
more than two times as large, also occurring much ear-
lier. In all of the treated cases, the maximum rate of
increase is approximately the same. However there is a
clear difference in when the maximum occurs, with the
more effective treatments keeping the rate lower for
longer periods of time and having a maximum occurring
later in time. In the combined treatment of IAA and
DMSO, the delays in achieving the maximum rate of
growth are also combined, leading to a longer period
with a slow rate of growth.
Table 2 Observed and estimated values for the weight of Solid Ehrlich Carcinoma treated with combined IAA and
DMSO
Time Observed
weight
H3 Estimated
weight
H1 Estimated
weight
H2 Estimated
weight
Weibull Estimated
weight
Gompertz Estimated
weight
9.00 0.21 0.21 0.21 0.21 0.21 0.21
13.0 0.39 0.33 0.27 0.27 0.24 0.32
17.0 0.49 0.46 0.36 0.36 0.30 0.46
21.0 0.65 0.59 0.48 0.49 0.40 0.64
29.0 0.89 0.96 0.86 0.87 0.80 1.15
33.0 1.13 1.21 1.15 1.15 1.11 1.48
37.0 1.49 1.53 1.51 1.51 1.51 1.85
40.0 1.89 1.83 1.83 1.84 1.86 2.17
43.0 2.31 2.18 2.21 2.22 2.26 2.50
49.0 3.05 3.04 3.01 3.12 3.17 3.24
55.0 4.05 4.08 4.10 4.15 4.16 4.04
57.0 4.51 4.45 4.45 4.50 4.50 4.32
60.0 4.96 5.00 4.96 5.01 5.00 4.74
66.0 5.91 6.01 5.90 5.95 5.92 5.61
72.0 6.86 6.78 6.66 6.71 6.68 6.49
74.0 7.09 6.97 6.87 6.91 6.90 6.78
78.0 7.21 7.24 7.23 7.26 7.25 7.35
82.0 7.35 7.40 7.50 7.52 7.52 7.91
Figure 1 Growth of tumor biomass under combined IAA/DMSO
treatment compared to H3 and Gompertz growth curve
estimates.
Table 3 Accuracy of models in estimating growth of solid
Ehrlich carcionma with combined treatment of IAA and
DMSO
H3 H2 H1 Weibull Gompertz
AIC -37.23951 -25.47660 -24.96665 -18.38632 7.53500
RMS 0.006 0.012 0.012 0.017 0.076
R
2 0.999 0.999 0.999 0.998 0.990
MARE 0.0367 0.0598 0.0594 0.0819 0.0959
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is 0.407303 grams per day, occurring on day 19.6933.
For the tumors treated with only iodoacetate, the maxi-
mum rate of growth is 0.192412 grams per day, occur-
ring on day 37.3535. The tumors treated with only
dimethylsulfoxide have a maximum rate of growth of
0.192293 grams per day, occurring on day 46.9909.
Finally the tumors with the combined treatment of
iodoacetate and dimethylsulfoxide have a maximum rate
of growth of 0.184104 grams per day, occurring on day
57.2509. It is interesting that all of the treated cases dis-
play approximately the same level for the maximum rate
of growth. In all cases, this rate is less than half of the
untreated tumors, displaying the effectiveness of all
three treatments. However, the treatment with iodoace-
tate is the least effective of these, with the maximum
occurring sooner, at time 37.3535 days, while the com-
bined treatment is the most effective, as the rate
remains lower for a longer period of time and does not
reach the maximum until day 57.2509. The article of
Fahim et al. [8] claimed a potential synergism between
the iodoacetate and dimethylsulfoxide in the combined
treatment. The combining of the effects of these two
treatments can be seen in the graphs. The maximum
rate in the combined treatment only lowers slightly,
however the time of that maximum is shifted further to
the right in time, as if the two treatments are combining
their effects.
Discussion
I nt h ec o m p a r i s o no fm o d e l sw eo b s e r v e dt h a tt h e
hyperbolastic models perform with a greater degree of
accuracy than either the Weibull or Gompertz models.
In particular H3 has the highest level of accuracy, con-
siderably better than any of the other competing models.
The hyperbolastic models were designed for flexibility in
modelling biological growth, allowing for flexibility in
the time at which the growth becomes self-limiting and
flexibility in the manner in which the rate goes to zero
as the population approaches the carrying capacity.
Growth of multicellular tumor spheroids is well known
to be self-limiting and fits well into this form of growth.
The H3 model is particularly effective, as has also been
the case in other comparative studies, i.e. [1], [2], [3],
and its strength is in its flexibility to fit biological
10 20 30 40 50 60 70 80
Day
0.05
0.10
0.15
0.20
0.25
0.30
Growth Rate
Figure 2 Rate of growth of tumor biomass under combined
IAA/DMSO treatment as measured by H3 and Gompertz
growth curves.
Figure 3 Growth of tumor biomass for each treatment using H3 model.
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we see that some of the flexibility originates from the
time dependence in the term

 tt ++ 1
2 ()
which allows the population to approach M more flex-
ibly than using only a static a, but also reduces to a sta-
tic a when θ =0 .
In assessing a treatment it is important to use the
most accurate model and find the most accurate predic-
tions. In comparing the most accurate model H3 with
Gompertz, the model most prevalently used, we
observed that H3 performs significantly better, while the
results according to the Gompertz model can be off by
a significant amount. Particularly in comparison of the
rates of growth, as in Figure 4, the distance between the
Gompertz model and the actual values is considerable.
With the accuracy of the H3 model, we can be certain
that the comparative analysis of the treatments, as illu-
strated in Figure 3 and Figure 4, is representative of the
actual data, although the same would not be true for
the Gompertz model. A comparative analysis of treat-
ment of solid Ehrlich carcinoma by treatments of IAA
alone, DMSO alone, or a combined treatment of IAA
and DMSO revealed that each of these treatments sig-
nificantly delayed tumor growth, cutting the maximum
rate of growth to less than half the original untreated
tumor, and delaying the time for the maximum rate of
growth from 19.6933 days to anywhere from 37.3535 to
5 7 . 2 5 0 9 ,i . e .b yaf a c t o ro ft w ot ot h r e e .T h i sy i e l d sa
good quantitative assessment of the treatment effective-
ness. Furthermore the analysis helps to describe the
means by which the two treatments combine. In the
combined treatment, the maximum rate of growth is
depressed only slightly, but the main impact comes in
t h ed e l a yo ft h et i m eo ft h emaximum rate, to approxi-
mately 10 to 20 days later than the single treatments.
An accurate representation and understanding of
growth dynamics of tumors can be used by physicians
in designing optimal treatment strategies or by scientists
in analyzing the factors leading to deceleration of
growth in multicellular tumor spheroids. In order to
have the most accurate information and make the best
decisions, it is valuable to have the increased precision
available in the H3 model. In designing a treatment plan
it is helpful to know the magnitude of growth and the
time at which the growth rate is maximized, and H3
can estimate these more accurately than other models.
It is also possible to measure the effect of any given
treatment on the tumor growth, as illustrated in Figures
3 and 4 and the associated discussion. Furthermore a
multivariable version of the H3 model is available, and
the multivariable model can measure the effects of
explanatory variables, such as the level of a given drug
applied in a treatment.
Conclusions
All three models H1, H2, and H3 proved successful in
modeling solid Ehrlich carcinoma growth under the
combined treatment with iodoacetate and dimethylsulf-
oxide, while the hyperbolastic model H3 had the least
Absolute Relative Error as well as the least Residual
20 30 40 50 60 70 80
Days
0.1
0.2
0.3
0.4
Rate of Change of Biomass
Figure 4 Rate of growth for tumor biomass for each treatment using H3 model.
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tic models was 0.999. The Mean Absolute Relative Error
was also very small, ranging from 0.0367 for H3 to
0.0598 for H2. The most accurate model, H3, was used
to compare growth under various treatments, for the
cases of the combined treatment, treatment with iodoa-
cetate alone, treatment with dimethylsulfoxide alone,
and the untreated control. The comparative analysis of
the growth rates shows comparable maximum rates of
growth of the tumors for all three cases of treated
tumors, less than half of the maximum growth rate for
the untreated tumor. But in the more effective treat-
ments, the tumor grows more slowly at the outset, and
the maximum rate is delayed to a later time. In the
combined treatment of IAA and DMSO, the delays in
achieving the maximum growth rates are combined to
give an even longer period of slow growth before the
maximum growth rate is achieved. This analysis sup-
ports the claims of Fahim et al. [8] that the anti-cancer
drugs iodoacetate and dimethylsulfoxide can combine to
form a greater effect because their methods of action
are complementary. The hyperbolastic models prove to
be effective in representing and analyzing the tumor cell
growth dynamics.
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